Neurology

Back to articles

Telcagepant: The next blockbuster migraine treatment?

KEY POINT

Treatment with telcagepant 300 mg, an investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist, had efficacy comparable to zolmitriptan (Zomig—AstraZeneca) 5 mg for the acute treatment of moderate or severe migraine attacks with a lower incidence of adverse events.